Spectrum pattern

RX STRENGTH AZELASTINE HCL 205.5 MCG NOW OTC!

A FASTER* COUNTDOWN TO ONSET OF RELIEF WITH FLEXIBLE PRN DOSING1-9

 

 

 

 

 

 

 

 

 

 

Introducing the first10 and only11 OTC nasal antihistamine spray—for adults and children age 6+9*

*Compared with other steroid allergy sprays, on day 1.

SEE PRODUCT DETAILS

PRN NASAL SYMPTOM RELIEF THAT STARTS WORKING IN 30 MINUTES1,8,*

30 minutes icon

Astepro® Allergy is different than INS sprays

  • Starts working in 30 minutes1,8,† while INS sprays take hours to start to provide relief. Can take between 3 and 14 days to reach maximum efficacy levels2-7,‡
  • Flexibility to dose PRN, once or twice a day, versus the leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior9,12,§
Steroid-free icon

Powerful, steroid-free nasal symptom relief for up to 24 hours9

  • Relief of indoor and outdoor allergies of nasal congestion, runny nose, itchy nose, and sneezing, without steroids or an additional decongestant9
  • The same as prescription Astepro® Allergy (azelastine HCL 205.5 mcg) nasal spray9,13,14
Child icon

FDA approved for children age 6+

  • Steroid-free relief of nasal allergy symptoms including congestion9
  • Dosing as needed
  • Does not have a label warning regarding pediatric growth suppression9

*Compared with other steroid allergy sprays, on day 1.

SEE HOW ASTEPRO COMPARES TO INS1-9, 15-18

Table comparing Astepro Allergy with INS sprays

INS, intranasal steroid.
*Compared with other steroid allergy sprays, on day 1.
On day 1.
INS onset based on various product information; time to maximum efficacy depends on the INS brand.
§In a survey of allergy patients that included nasal spray users (n=732), 42% of patients said they administer their INS “some days and not others.”
Up to twice daily.

REFERENCES:
1. Data on file. Bayer. Study 20877. Onset of action. 2. Flonase® website. Accessed March 2, 2022. https://www.flonase.com/faqs/ 3. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 4. GSK health partner website. Accessed March 2, 2022. https://www.gskhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 5. Nasacort® website. Accessed March 2, 2022. https://www.nasacort.com/allergy-nasal-spray-nasacort-faqs/ 6. Nasacort® AQ. Prescribing information. Sanofi-aventis U.S. LLC; 2008. 7. Rhinocort website. Accessed November 11, 2021. https://www.rhinocort.com/allergy-nasal-spray/adult-otc-spray 8. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296 9. NDA 213872. 10. FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed March 2, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use 11. Data on file. Bayer. IRI data. Only OTC AH. 12. Data on file. Bayer. Habits and practices. 13. Astepro®. Prescribing information. Meda Pharmaceuticals Inc; 2018. 14. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed October 28, 2021. https://www.fda.gov/media/100100/download 15. Flonase® Drug Facts Label. NDA205434. 16. Nasacort® Drug Facts Label. NDA020468. 17. Rhinocort® Drug Facts Label. NDA020746. 18. Rhinocort Aqua®. Prescribing information. AstraZeneca; 2010.

Spectrum pattern